Non-small cell lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Retrospective study: Patients who were previously diagnosed with lung cancer or colorectal cancer and have undergone high-throughput sequencing testing; 2.Retrospective study: The collected indicators include patients' clinical information (such as age, gender, pathological type, stage, treatment plan, and prognosis), high-throughput sequencing-related data (such as sampling time, specimen type, detection methods, gene mutation types and frequencies, gene copy number variations, fusion genes, etc.), other tumor treatments, monitoring-related tests and their results (PCR, immunohistochemistry, imaging tests, etc.), testing medical costs, treatment costs, and so on. 3. Prospective study: (1) Recruit from February 2025 to February 2029. During the clinical diagnosis and treatment process, or through screening based on the Hospital's LIS System (Laboratory InformationSystem) and HIS system (Hospital InformationSystem) to meet the requirements, And patients who voluntarily participated in this study. (2) Include patients with clinically confirmed lung cancer or colorectal cancer.
Exclusion criteria
Exclusion criteria: 1.Retrospective study: None 2. Prospective study: (1) Age <18 years old; (2) Incomplete clinical information; (3) Lactation and pregnancy; (4) Suffering from severe mental disorders such as epilepsy, etc. (5) Patients who refuse to sign informed consent; (6) Patients who, as determined by the researcher, are not suitable for inclusion in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene locus detection rate;Medical costs;Turnaround Time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Progression Free Survival; | — |
Countries
China
Contacts
West China Hospital of Sichuan University